Apellis Pharmaceuticals (APLS)
(Delayed Data from NSDQ)
$28.83 USD
+0.76 (2.69%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $28.88 +0.05 (0.17%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
Price, Consensus and EPS Surprise
APLS 28.83 +0.76(2.69%)
Will APLS be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for APLS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for APLS
Apellis' Q3 Loss Wider Than Expected, Syfovre Drives Revenues Y/Y
Apellis Pharmaceuticals (APLS) Reports Q3 Earnings: What Key Metrics Have to Say
APLS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Apellis Pharmaceuticals, Inc. (APLS) Reports Q3 Loss, Lags Revenue Estimates
Editas Medicine (EDIT) Reports Q3 Loss, Misses Revenue Estimates
Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Other News for APLS
Apellis price target lowered to $30 from $35 at Scotiabank
Apellis price target lowered by $5 at Scotiabank, here's why
Lululemon To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday
Apellis Pharmaceuticals (APLS) Gets a Hold from Scotiabank
Oppenheimer Sticks to Their Buy Rating for Apellis Pharmaceuticals (APLS)